Erika Parker Zavod is Senior Vice President, Strategy and Planning, Research and Development and leads Acadia’s research and development strategy and planning efforts in providing compound-level program management leadership and alliance management support.
Ms. Zavod joined Acadia in 2018 as Executive Director, Clinical Development Strategy and Planning and was promoted to Vice President, Research and Development Strategy and Planning, Biometrics and Medical Writing in 2021 to lead cross-functional planning and strategy initiatives in addition to progressing drug development plans. She was promoted to her current role in 2023.
With more than two decades of clinical leadership, operational oversight, and strategic planning experience, Ms. Zavod joined Acadia from Teva Pharmaceuticals (Cephalon), where she began in 2011 as Associate Director, Clinical Project Management, Pain/CNS. She rose to Director, Global Clinical Operations, Immunology and then to Senior Director, Chief of Staff/CMO and Head of Clinical Data Sciences, where she was responsible for planning and directing administrative, operational and strategic activities in support of the Chief Medical Organization (Early and Late Stage Clinical Development, Biometrics, Operations, Global Medical Affairs, Small Molecule Discovery and Pharmacovigilance).
Ms. Zavod began her career in Data Management and then as a Clinical Research Associate, were she oversaw clinical trial monitoring as an independent consultant, and worked as Senior Clinical Program Manager/CNS at Wyeth before joining Cephalon, which was acquired by Teva in 2011.
She holds a Bachelor of Arts in Psychology/Neuroscience from Clark University and a Master of Science in Pharmaceutical QA/RA from Temple University and earned her Master Six Sigma Black Belt from Villanova University.